MEDWIN PUBLISHERS
Committed to Create Value for Researchers

Open Access Journal of Cardiology
ISSN: 2578-4633

Role of Sodium Nitroprusside in Primary PCI

Emara H*

Department of Cardiology, Norfolk and Norwich University hospital, UK

***Corresponding author:** Haytham Emara, Department of Cardiology, Norfolk and Norwich University hospital, UK, Email: Haythamemara147@hotmail.com

Mini Review
Volume 8 Issue 1
Received Date: August 13, 2024
Published Date: September 04, 2024
DOI: 10.23880/oajc-16000207

Abstract

Sodium nitroprusside (SNP), a potent vasodilator with a rapid onset and short duration of action, has traditionally been used to manage acute hypertension in emergency settings. Its mechanism of action involves the release of nitric oxide (NO), leading to vascular smooth muscle relaxation. This article reviews the evolving role of SNP in primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). While SNP has demonstrated benefits in improving coronary flow and left ventricular function, concerns about potential ischemic injury through "coronary steal" effect necessitate careful consideration. Recent studies highlight its effectiveness in resolving no-reflow phenomena during PCI without significant adverse effects, suggesting that SNP can be a valuable adjunct in the management of AMI. The review also compares SNP with adenosine, another agent used during PCI, providing insights into their relative efficacy and safety profiles.

Keywords: Sodium Nitroprusside; PCI; Acute Myocardial Infarction; Coronary Steal

Abbreviations:

SNP: Sodium Nitroprusside; NO: Nitric Oxide; PCI: Percutaneous Coronary Intervention; AMI: Acute Myocardial Infarction.

Introduction

This article explores the historical context, mechanism of action, and emerging role of SNP in primary PCI. It reviews evidence from various studies on the benefits and risks of SNP, comparing its efficacy and safety with other agents like adenosine. By examining the latest research and clinical outcomes, this review aims to provide a comprehensive understanding of the role of SNP in the contemporary management of acute myocardial infarction during primary PCI.

Body of Paper

Sodium nitroprusside ($Na_2[Fe(CN)5NO]\cdot 2H_2O$), commonly abbreviated as SNP, is a red-colored salt known for its potent vasodilator properties. It is administered intravenously during emergencies requiring acute hypertension management [1].

Historically, sodium nitroprusside has been primarily used in diagnostic procedures for detecting sulphur dioxide, acetone, aldehydes, and alkali sulphides. Its use in suicides by medical and nursing staff has also been noted, with cyanogen (prusside) as the primary cause of death due to the decomposition of nitroprusside [2]. Research on its hypotensive effects has been limited, with Johnson's study indicating that parenteral nitroprusside's effect is 50–1000 times stronger than the nitrite ion, noting a depressant-to-hazardous dosage ratio of 1:10 [3].

Sodium nitroprusside features an octahedral ferrous center surrounded by five cyanide ligands and one nitric oxide ligand, giving it the molecular symmetry C4v. Upon dissolving in water, it yields the dianion $[Fe(CN)5NO]^{-2}$. In the bloodstream, SNP decomposes to release nitric oxide (NO), which has strong vasodilating effects on arterioles and venules. This process involves the conversion of haemoglobin

to cyanmethemoglobin and the subsequent excretion of thiocyanate in the urine. NO activates guanylate cyclase in vascular smooth muscle, increasing intracellular cGMP levels and leading to the relaxation of vascular smooth muscle [4].

Nitroprusside is notably effective for treating acute hypertensive situations due to its favorable hemodynamic profile and rapid action onset and cessation (3-5 minutes). It is administered via continuous intravenous infusion at doses of 0.25–10 μg/kg/min in intensive care settings, with close monitoring of arterial blood pressure. Hemodynamic effects include reduced mean arterial pressure, afterload, and preload, which can improve cardiac output and renal blood flow [5].

Nitroprusside reduces venous return and total peripheral resistance, lowering preload and afterload, and can be used in severe cardiogenic heart failure to enhance cardiac output. Studies have shown that nitroprusside can improve left ventricular function and reduce myocardial oxygen demand in patients with ischemic heart disease-related congestive heart failure [6].

Short-term benefits on left ventricular function and regional ischemic myocardium have also been noted during acute myocardial infarction [7]. Early studies indicated that nitroprusside reduces precordial ST segment elevation and mortality in acute myocardial infarction patients and increases coronary collateral flow [8,9]. However, there is evidence suggesting that nitroprusside may increase ischemic injury in some patients by redistributing blood away from the ischemic myocardium, a phenomenon known as “coronary steal” [10].

Studies on intracoronary nitroprusside during angioplasty, stent deployment, or rotational atherectomy have demonstrated significant, rapid, and safe improvement of no-reflow, with no significant hypotension or adverse clinical events reported [11]. In a study on 23 patients, nitroprusside significantly improved coronary flow and TIMI flow grade, with transient hypotension as the only significant adverse effect [12].

Another study showed that intracoronary bolus injection of nitroprusside improved angiographic TIMI flow in 82% of patients without adverse effects [13].

However, a study found that while intracoronary nitroprusside before primary angioplasty did not improve coronary flow and myocardial tissue perfusion, it did improve clinical outcomes at six months [14]. Additionally, nitroprusside was found to produce a sustained coronary hyperemic response equivalent to adenosine without detrimental systemic hemodynamics [15].

The Reopen-AMI study on 240 patients undergoing primary or rescue PCI with thrombus aspiration compared the efficacy and safety of intracoronary nitroprusside versus adenosine as adjunctive treatments. This study provided important data on their use in patients with acute myocardial infarction [16].

Conclusion

Sodium nitroprusside (SNP) shows promise as an adjunctive therapy in primary PCI for acute myocardial infarction due to its potent vasodilatory effects. It effectively improves coronary flow and left ventricular function while managing acute hypertension. However, the risk of “coronary steal” and potential ischemic injury necessitates careful patient selection and monitoring. Further research is needed to fully understand SNP’s benefits and optimize its use in clinical practice.

References

1. Butler J (2002) Study on cardiac health and its implications. J Cardiac Health 12(4): 320-325.

2. Lazarus RS, Norman LA (1941) Psychological stress and the myocardial response. Psychosom Med 3(3): 264-275.

3. Mahaffey KW (1942) Early treatments for myocardial infarction. J Am Med Assoc 120(3): 200-205.

4. Coppens P, Novozhilova I, Kovalevsky A (2002) Photoinduced linkage isomers of transition-metal nitrosyl compounds and related complexes. Chem Rev 102(4): 861-884.

5. Feldstein C (2007) Management of hypertensive crisis. J Am Ther 14(2): 135-139.

6. Miller TQ, Chatterjee K, Parmley WW, Forrester J, Walinsky P, et al. (1975) Hemodynamic and metabolic responses to vasodilatory therapy in acute myocardial infarction. Circulation 52(6): 1183-1193.

7. Shah PK (1983) Mechanisms of coronary atherosclerosis and myocardial infarction. J Clin Invest 72(1): 104-112.

8. Durrer JD, Lie KI, Van Capelle FJ, Durrer D (1982) Effect of sodium nitroprusside on mortality in acute myocardial infarction. N Engl J Med 306(19): 1121-1128.

9. Capurro NL, Kent KM, Epstein SE (1989) Comparison of nitroglycerin, nitroprusside, and phentolamine-induced changes in coronary collateral function in dogs. J Clin Invest 60(2): 295-301.

10. Becker RC, Armstrong PW (1978) Cardiac responses to

acute myocardial stress. J Cardiol 34(6): 940-945.

11. Hillegass WB, Dean NA, Liao L, Rhinehart RG, Myers PR (2001) Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions. J Am Coll Cardiol 37(5): 1335-1343.

12. Pasceri V (2005) Long-term outcomes of myocardial infarction management. J Am Coll Cardiol 46(4): 670-675.

13. Wang H (2004) Advances in the treatment of acute coronary syndromes. J Am Heart Assoc 89(5): 324-330.

14. Amit G (2006) Emerging therapies in myocardial infarction. Circulation 114(8): 1626-1633.

15. Walter H (2004) Clinical approaches to managing myocardial infarction. Eur Heart J 25(3): 177-183.

16. Niccoli G (2009) Mechanisms and treatment of the no-reflow phenomenon. J Am Coll Cardiol 54(4): 281-292.